London (UK) – Stallergenes Greer plc (the “Company”) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today provided an update on activities from its Antony, France site following the resumption of manufacturing and distribution activities on 10 March 2016.
As part of the Named Patient Product (NPP) voluntary recall related to the implementation of the ERP system, quality analyses were conducted using a representative sample of returned products. To date, results from these analyses show that the allergen content of the product vials complies with required specifications.
Furthermore, the Company’s “RESTART” plan, which is designed to regain the Company’s global leadership by focusing on production, logistics and commercial capabilities in the EU/International region, helped resume product delivery to patients with an average lead time of two weeks. More than 250,000 treatments have been delivered since the restart, and the Company is able to meet patient demand for the most prevalent allergens.
“The results of NPP testing validates our confidence in the quality of our products,” said Michele Antonelli, Stallergenes Greer Executive Vice President, Europe and Rest of the World. “I am very pleased that we are able to meet the needs of patients and physicians once again with the help of our RESTART plan and we will continue to ensure high quality standards – both in our products and technical operations capabilities. The health and safety of patients has always been and remains our top priority”.
Learn more about our product availability on our website: